Akanda Corp (AKAN)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
AKAN
Akanda Corp
$5.31
-16.90%
HEALTHCARE · Cap: $4.31M
TAK
Takeda Pharmaceutical Co Ltd ADR
$17.09
-0.93%
HEALTHCARE · Cap: $55.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 1745861672% more annual revenue ($4.51T vs $258,080). AKAN leads profitability with a 0.0% profit margin vs -3.4%. TAK earns a higher WallStSmart Score of 57/100 (C).
AKAN
Avoid26
out of 100
Grade: F
TAK
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+80.2%
Fair Value
$4.79
Current Price
$5.31
$0.52 discount
Intrinsic value data unavailable for TAK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Revenue surging 21.9% year-over-year
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 330.2% YoY
Large-cap with strong market position
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
3.9% revenue growth
ROE of 2.5% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AKAN
The strongest argument for AKAN centers on Debt/Equity, Revenue Growth. Revenue growth of 21.9% demonstrates continued momentum.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.45 suggests the stock is reasonably priced for its growth.
Bear Case : AKAN
The primary concerns for AKAN are EPS Growth, Market Cap, Profit Margin.
Bear Case : TAK
The primary concerns for TAK are Revenue Growth, Return on Equity, Free Cash Flow.
Key Dynamics to Monitor
AKAN profiles as a growth stock while TAK is a turnaround play — different risk/reward profiles.
AKAN carries more volatility with a beta of 14.16 — expect wider price swings.
AKAN is growing revenue faster at 21.9% — sustainability is the question.
AKAN generates stronger free cash flow (-8M), providing more financial flexibility.
Bottom Line
TAK scores higher overall (57/100 vs 26/100). AKAN offers better value entry with a 80.2% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Akanda Corp
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Akanda Corporation. The company is headquartered in New Romney, the United Kingdom.
Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?